EMEA-001315-PIP02-16-M01

Key facts

Active substance
Fevipiprant
Therapeutic area
Pneumology-allergology
Decision number
P/0157/2019
PIP number
EMEA-001315-PIP02-16-M01
Pharmaceutical form(s)
  • Tablet
  • Chewable tablet
  • Age-appropriate oral liquid dosage form
Condition(s) / indication(s)
Treatment of asthma
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Limited

Tel. +41 613241111
E-mail: paediatric.enquiries@novartis.com

Decision type
RP: decision refers to a refusal on a proposed Paediatric Investigation Plan

Decision

How useful was this page?

Add your rating